000
| 01826cam 2200337zi 4500 |
---|
001 | 9.897250 |
---|
003 | CaOODSP |
---|
005 | 20221107174535 |
---|
006 | m o d f |
---|
007 | cr cn||||||||| |
---|
008 | 201005s2020 onca obs f000 0 eng d |
---|
040 | |aCaOODSP|beng|erda|cCaOODSP |
---|
043 | |an-cn--- |
---|
086 | 1 |aH82-52/2020E-PDF |
---|
245 | 00|aPMPRB guidelines. |
---|
246 | 13|aPatented Medicine Prices Review Board guidelines |
---|
264 | 1|aOttawa, ON : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |c[2020] |
---|
300 | |a1 online resource (39 pages) |
---|
336 | |atext|btxt|2rdacontent |
---|
337 | |acomputer|bc|2rdamedia |
---|
338 | |aonline resource|bcr|2rdacarrier |
---|
500 | |aIssued also in French under title: Lignes directrice du CEPMB. |
---|
500 | |aIssued also in HTML format. |
---|
504 | |aIncludes bibliographical references. |
---|
520 | 2 |a"The Guidelines provide information on the PMPRB’s general approach to the price review process and investigations. They supersede all previous guidance documents, policy communiqués and written or verbal statements of any kind by the PMPRB regarding the administration of the price review process and investigations, including all previous versions of the PMPRB’s Compendium of Guidelines, Policies and Procedures."--II, Interpretation, page 3. |
---|
650 | 0|aDrugs|xPrices|xGovernment policy|zCanada. |
---|
710 | 1 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body. |
---|
775 | 08|tLignes directrice du CEPMB.|w(CaOODSP)9.897251 |
---|
856 | 40|qPDF|s513 KB|uhttps://publications.gc.ca/collections/collection_2021/cepmb-pmprb/H82-52-2020-eng.pdf |
---|
856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/legislation/about-guidelines/guidelines.html |
---|